Duloxetine for the treatment of fibromyalgia

Drugs of Today

Volumn 44, Issue 10, 2008, Pages 725-734

  Acuña, Carmen ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FIBROMYALGIA; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENTAL PERFORMANCE; NAUSEA; NOCICEPTION; NORADRENERGIC SYSTEM; PAIN; PHYSICAL PERFORMANCE; QUALITY OF LIFE; REVIEW; SEROTONIN RELEASE; VISUAL ANALOG SCALE; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FIBROMYALGIA; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES;

EID: 58949103419     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.10.1269675     Document Type: Review

References (42)

1. Russell, I.J., Raphael, K.G. Fibromyalgia syndrome: Presentation, diagnosis, differential diagnosis, and vulnerability. CNS Spectr 2008, 13(3 Suppl 5): 6-11.
2. Birtane, M., Uzunca, K., Tastekin, N., Tuna, H. The evaluation of quality of life in fibromyalgia syndrome: A comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol 2007, 26(5): 679-84.
3. Ubago Linares, M.C., Ruiz-Pérez, I., Bermejo Pérez, M.J. et al. Analysis of the impact of fibromyalgia on quality of life: associated factors. Clin Rheumatol 2008, 27: 613-9.
4. Carmona, L., Ballina, J., Gabriel, R., Laffon, A.; EPISER Study Group. The burden of musculoskeletal diseases in the general population of Spain: Results from a national survey. Ann Rheum Dis 2001, 60(11): 1040-5.
5. Gamero Ruiz, F., Gabriel Sánchez, R., Carbonell Abello, J., Tornero Molina, J., Sánchez-Magro, I. El dolor en las consultas de Reumatología españolas: Estudio epidemiológico EPIDOR. Rev Clin Esp 2005, 205(4): 157-63.
6. Eraso, R.M., Bradford, N.J., Fontenot, C.N., Espinoza, L.R., Gedalia, A. Fibromyalgia syndrome in young children: Onset at age 10 years and younger. Clin Exp Rheumatol 2007, 25(4): 639-44.
7. Michels, H., Gerhold, K., Häfner, R. et al. Juvenile fibromyalgia syndrome. Schmerz 2008, 22(3): 339-48.
8. Carretero Quevedo, B., Martín Vázquez, M.J., Pradana, M.L. et al. Depresión y fibromialgia: estudio de una muestra. Actas Esp Psiquiatr 2007, 35(Suppl. 1): 151-2.
9. Blotman, F., Bannwarth, B., Thomas, E. et al. Prevalence of fibromyalgia in Europe - a tip of the iceberg. EULAR 2008. Annu Eur Congr Rheumatol (June 11-14, Paris) 2008, Abst AB0883.
10. Gur, A., Oktayoglu, P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment. Curr Pharm Des 2008, 14(13): 1274-94.
11. Littlejohn, G.O. Balanced treatments for fibromyalgia. Arthritis Rheum 2004, 50(9): 2725-9.
12. Micó, J.A. Farmacología de duloxetina. Rev Soc Esp Dolor 2006, 13(Suppl. 3): 4-9.
13. Jaracz, J., Rybakowski, J. Depression and pain: Novel clinical, neurobiological and psychopharmacological data. Psychiatr Pol 2005, 39(5): 937-50.
14. Perahia, D.G., Pritchett, Y.L., Desaiah, D., Raskin, J. Efficacy of duloxetine in painful symptoms: An analgesic or antidepressant effect? Int Clin Psychopharmacol 2006, 21(6): 311-7.
15. Center for Drug Evaluation and Research. Food and Drug Administration. What's new by date. 18 junio, 2008. http://www.fda.gov/cder/whatsnew.htm
16. Carville, S.F., Arendt-Nielsen, S., Bliddal, H. et al.; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008, 67(4): 536-41.
17. Cowen, P.J., Ogilvie, A.D., Gama, J. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Curr Med Res Opin 2005, 21(3): 345-56.
18. Brecht, S., Courtecuisse, C., Debieuvre, C. et al. Efficacy of duloxetine in the treatment of unspecific pain associated with depression. 160th Ann Meet Am Psychiatr Assoc (May 19-24, San Diego)2007, Abst NR782.
19. Lilly submits sNDA to the FDA for Cymbalta in chronic pain. Prous Science Daily Essentials. May 30, 2008. http://www.dailydrugnews.com
20. Mummaneni, R.B., Pasnoor, M., Khan, S. et al. Duloxetine treatment for painful peripheral neuropathy and headaches. Neurology 2006, 66(5 Suppl. 2): Abst. P05.106.
21. Fusco, B.M., Agro, F.E. Duloxetine as a therapeutic alternative for chronic tension headache: An open label study. 13th Congr lnt Headache Soc (June 28-July 1, Stockholm) 2007, Abst D094.
22. Detke, M.J., Lu, Y., Goldstein, D.J., Hayes, J.R., Demitrack, M.A. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002, 63(4): 308-15.
23. Detke, M.J., Lu, Y., Goldstein, D.J., Mc Namara, R.K., Demitrack, M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002, 36(6): 383-90.
24. Brannan, S.K., Mallinckrodt, C.H., Brown, E.B. et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005, 39(1): 43-53.
25. Raskin, J., Wiltse, C.G., Siegal, A. et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007, 164(6): 900-9.
26. Fava, M., Mallinckrodt, C.H., Detke, M.J., Watkin, J.G., Wohlreich, M.M. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004, 65(4): 521-30.
27. Perahia, D., Quail, D., Desaiah, D., Montejo, A.-L. Switch to duloxetine in SSRI non- and partial responders: Effects on painful physical symptoms of depression. Am Psychiatr Assoc Annu Meet (May 19-24, San Diego) 2007.
28. Westanmo, A.D., Gayken, J., Haight, R. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health Syst Pharm 2005, 62(23): 2481-90.
29. Farrar, J., Pritchett, Y., Robinson, M., Watkin, J., Chappell, A. Clinical importance of changes in pain intensity: An analysis of data from clinical trials of duloxetine in pain disorders. 25th Annu Sci Meet Am Pain Soc (May 3-6, San Antonio) 2006, Abst 748.
30. Pritchett, Y., McCarberg, B., Watkin, J., Chappell, A., Robinson, M. Duloxetine in the management of diabetic peripheral neuropathic pain: Response profile. Neurotherapeutics 2006, 3: 407.
31. Perahia, D.G., Pritchett, Y.L., Desaiah, D., Raskin, J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006, 21(6): 311-7.
32. Arnold, L.M., Lu, Y., Crofford, L.J. et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50(9): 2974-84.
33. Arnold, L.M., Rosen, A., Pritchett, Y.L. et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119: 5-15.
34. Arnold, L.M., Pritchett, Y.L., D'Souza, D.N. et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007, 16: 1145-56.
35. Russell, I.J., Mease, P.J., Smith, T.R. et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136(3): 432-44.
36. Chappell, A., Bradley, L., Wiltse, C., D'Souza, D.N., Spaeth, M. Duloxetine 60-120 mg versus placebo in the treatment of fibromyalgia syndrome. Am Coll Rheumatol/Assoc Rheumatol Health Prof (ACR/ARHP) Annu Sci Meet (Nov 6-11, Boston) 2007, Abst 157.
37. Geiser, J., Quinlan, T., Lobo, E. Pharmacokinetic-pharmacodynamic modeling of the effects of duloxetine on pain score and patient's global impression of improvement in patients with fibromyalgia. Clin Pharmacol Ther 2008, 83(Suppl. 3): Abst OII-D-3.
38. Mease, P., Russell, I.J., Kajdasz, D. et al. Long-term safety, tolerability, and effectiveness of duloxetine in the treatment of fibromyalgia. Ann Rheum Dis 2008, 67(Suppl. II): 262.
39. Arnold, L., Clauw, D., Wohlreich, M. et al. Efficacy of duloxetine in patients with fibromyalgia: pooled anal ysis of four placebo-controlled clinical trials. Am Pain Soc Annu Meet (May 8-10, Tampa) 2008, Abst 286.
40. Chappell, A.S., Littlejohn, G., Kajdasz, D., D'Souza, D.N., Moldofsky, H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Ann Rheum Dis 2008, 67(Suppl. II): 253.
41. Gahimer, J., Wernicke, J., Yalcin, I. et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007, 23(1): 175-84.
42. Wernicke, J., Lledó, A., Raskin, J., Kajdasz, D.K., Wang, F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007, 30(5): 437-55.